LIFEASSAYS® RESOLVES ON DIRECTED SHARE ISSUE
The board of LifeAssays AB (publ) has, with the authorization of the Annual General Meeting on the 20thof May 2016, decided to conduct a directed issue of 165,634,323 new B shares, equivalent to approximately 9.99 percent of the total number of outstanding shares and votes of the company. All B shares have been subscribed by Beijing St Grand Asset Management Co. Ltd. The subscription price is 0.039 SEK per B share and will provide the company with a total of 6,459,738.60 SEK, before deduction of issue costs. The subscription price is equivalent to the volume-weighted average share price for the company’s B shares during 20 trade days at NGM Equity immediately prior to the date of the resolution on the issue of shares. The subscription price is in ören rounding to one decimal place.
Following the issue of new shares, the company’s share capital increases by 3,312,686.46 SEK, through which the company’s share capital amounts to 36,439,551.14 SEK, divided into 1,821,977,557 B shares.
The purpose of the issue of new shares and the reason for deviating from the shareholders’ pre-emption rights is to provide the company with a new strategically important shareholder.
Beijing St Grand Asset Management will by its investment become one of LifeAssays® larger shareholders.
“ Asia, and China in particular, is seen by us as one of the Company’s most important markets in the coming years. Veterinarian medicine is growing very rapidly in China and St Grand’s knowledge of and presence on the Chinese market is seen by us as a great asset”, Anders Norling, chairman of the board of LifeAssays® AB, says.
“We have been studying LifeAssays® for some time and are happy to have been given the opportunity to take part in the company’s growth as owners. LifeAssays® is established on the Chinese market and is running projects with large commercial potential world-wide, within both veterinarian and human medicine. We look forward to participating in and to contribute to that development”, says Yugou Li .
This information is information that LifeAssays is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 12:45 CET on 9 March 2017.
For additional information please contact the CEO of LifeAssays AB, Anders Ingvarsson +46 46 286 54 00 or email: email@example.com
About LifeAssays®. NGM-listed LifeAssays® AB’s business concept is to develop, manufacture and sell diagnostic systems based on the company’s own and patented technology platform, MagnetoImmunoAssay (MIA). The company delivers safe and sturdy systems for fast and reliable analysis within veterinarian medicine. For more details please visit www.lifeassays.com
About Beijing St Grand Asset Management Co. Ltd. A Chinese investment company investing in companies from startups to established companies in different fields spanning from IT, Green energy, Consumer goods to Health Care. The company has offices in eight locations in China including Hong Kong and manage an investment portfolio including over 30 companies.
For more details, please visit: www.st-grand.com